Biotechnology News 18 October 2025

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine

21 October 2025

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading

21 October 2025

Biotechnology · Investing · Medical News · NASDAQ:SPRO · NYSE:GSK · Pharmaceuticals · Stock Market

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day finviz.com.

20 October 2025

Biotechnology · Financial News · Gene Editing · Investment · NASDAQ:BEAM · Stock Market

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as

20 October 2025

Biotechnology · Cancer Research · Clinical Trials · Investment News · NASDAQ:CELC · Stock Market

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Alliance Triggers Record Rally GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and

20 October 2025

Biotechnology · Health News · Investments · Medical Innovations · NASDAQ:GRAL · Stock Market

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17

20 October 2025

Biotechnology · Cancer Research · Financial Analysis · Investment News · NASDAQ:SLS · Stock Market

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months.

19 October 2025

Biotechnology · Healthcare Industry · Investment Analysis · NASDAQ:VKTX · Obesity Drugs · Stock Market

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1

19 October 2025

Biotechnology · Gene Editing · Healthcare Innovation · Investment Analysis · NASDAQ:CRSP · Stock Market

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission

18 October 2025

Biotechnology · Cancer Research · Healthcare Innovation · Investment News · NASDAQ:GRAL · Stock Market

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at

18 October 2025

Biotechnology · Investment Analysis · Leukemia Research · NASDAQ:SLS · Pharma News · Stock Market

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to

18 October 2025

Biotechnology · Financial News · Investing · NASDAQ:CMPS · NASDAQ:MNMD · NYSE:ABBV · Psychedelics · Stock Market

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the

18 October 2025

Biotechnology · Healthcare · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market

Biotechnology News 18 October 2025 - 21 October 2025